The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
In total, 22 dolphin brains were studied in which researchers noted that the animals presented alterations in their brain chemistry, changes most commonly found in humans who have Alzheimer's.